ResultsIQ

ResultsIQ › Latest results › Orchid Pharma Limited

Orchid Pharma Limited Q4 FY25 earnings call summary

NSE: ORCHPHARMA · BSE: 524372

Earnings call of 26 May 2025, summarised by AI from the filing.

Orchid Pharma Q4 FY25 sales ₹237 cr, up 9%; FY26 expected muted with 7-ACA mechanical completion delayed to December 2026.

Key takeaways

  1. FY26 guidance Management anticipates a muted FY26 given continued pricing pressure and 7-ACA capex ramp-up; mid-teen margin aspiration remains intact.
  2. 7-ACA delay Mechanical completion pushed to December 2026, a six-month increase from earlier estimates; first commercial product targeted March 2027.
  3. Enmetazobactam traction India product performing better than estimates; 10,000 patients reached in half year vs full-year plan of 10,000.
  4. Allecra insolvency Allecra insolvency filing in Germany clouds near-term US and international commercialization; royalty not received.

Original filing on BSE

Orchid Pharma Limited Q1 FY27 results

As filed: Revenue ₹304 cr (+76% year on year), EBITDA ₹14.0 cr (−7% year on year), PAT ₹3.2 cr (−79% year on year), EBITDA margin 4.6% (−407 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹368 cr (+55% year on year), EBITDA ₹30.2 cr (+8% year on year), PAT ₹25.8 cr (+17% year on year), EBITDA margin 8.2% (−363 bps). Score 66 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 363 bps year on year. Other income 31% of PBT. Tax rate 0%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +38.9% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹207 cr (−4% year on year), EBITDA ₹1.6 cr (−94% year on year), PAT −₹12.6 cr (−123% year on year), EBITDA margin 0.8% (−1,000 bps). Score 20 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit before exceptional items growth were well below it. EBITDA margin fell 1000 bps year on year. Share price after the results: −25.8% in 30 days (Nifty 500: −10.1%).
  • Q2 FY26: Revenue ₹194 cr (−13% year on year), EBITDA −₹1.0 cr (−103% year on year), PAT −₹6.0 cr (−122% year on year), EBITDA margin -0.5% (−1,000 bps). Score 20 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 1000 bps year on year. Profit fell 140% from last quarter. Share price after the results: +0.6% in 30 days (Nifty 500: −0.2%).
  • Q1 FY26: Revenue ₹173 cr (−29% year on year), EBITDA ₹15.0 cr (−53% year on year), PAT ₹15.0 cr (−48% year on year), EBITDA margin 8.7% (−444 bps). Score 7 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 444 bps year on year. Other income 79% of PBT. Tax rate 0%. Revenue fell 27% from last quarter. Share price after the results: −7.0% in 30 days (Nifty 500: +2.4%).
  • Q4 FY25: Revenue ₹237 cr (+9% year on year), EBITDA ₹28.0 cr (0% year on year), PAT ₹22.0 cr (−33% year on year), EBITDA margin 11.8% (−109 bps). Score 34 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 109 bps year on year. Tax rate 0%. Share price after the results: −5.1% in 30 days (Nifty 500: +1.7%).
  • Q3 FY25: Revenue ₹217 cr (−2% year on year), EBITDA ₹27.0 cr (−23% year on year), PAT ₹21.0 cr (−28% year on year), EBITDA margin 12.4% (−339 bps). Score 13 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 339 bps year on year. Other income 36% of PBT. Tax rate 0%. Profit fell 22% from last quarter.
  • Q2 FY25: Revenue ₹223 cr (+12% year on year), EBITDA ₹30.0 cr (+25% year on year), PAT ₹27.0 cr (+35% year on year), EBITDA margin 13.5% (+139 bps). Score 55 of 100, In line with trend. EBITDA margin rose 139 bps year on year. Other income 31% of PBT. Tax rate 0%. Not enough history for a trend yet: scored on growth alone. Revenue fell 9% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Orchid Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.